论文部分内容阅读
目的:探讨米格列奈和瑞格列奈在治疗新诊断2型糖尿病的临床价值比较。方法:将2010年1月至2012年12月间我院新诊断的120例2型糖尿病患者随机分为A、B两组,其中A组患者60例,采用瑞格列奈联合二甲双胍进行治疗,B组患者60例,采用米格列奈联合二甲双胍进行治疗。对两组患者血糖水平及12周后相应指标进行统计分析。结果:治疗3天后两组患者的空腹血糖及餐后血糖水平明显低于治疗前,B组患者血糖降低幅度大于A组(P<0.05);治疗12周后,两组空腹血糖及餐后血糖水平显著减小,B组减小程度高于A组;患者空腹及餐后胰岛素水平有一定的增加,B组增加程度高于A组;B组患者HbA1c的降低程度高于A组;两组同时还可以降低HOMA胰岛素的抵抗指数以及增大胰岛素的敏感指数,其中B组效果好于A组;B组患者出现低血糖的人次少于A组。结论:米格列奈与瑞格列奈分别联合二甲双胍可以短期降低新诊断2型糖尿病患者的血糖水平,在中期治疗后米格列奈联合二甲双胍可以更有效的改善患者糖尿病的各项指标。
Objective: To investigate the clinical value of mitiglinide and repaglinide in the treatment of newly diagnosed type 2 diabetes mellitus. Methods: A total of 120 newly diagnosed type 2 diabetic patients in our hospital from January 2010 to December 2012 were randomly divided into A and B groups, including 60 patients in group A, treated with repaglinide and metformin, Sixty patients in group B were treated with mitiglinide and metformin. Two groups of patients with blood glucose levels and 12 weeks after the corresponding indicators of statistical analysis. Results: The fasting blood glucose and postprandial blood glucose levels were significantly lower in both groups after 3 days of treatment than those in group B (P <0.05). After 12 weeks of treatment, the fasting blood glucose and postprandial blood glucose The level of HbA1c in group B was significantly lower than that in group A, while the level of HbA1c in group B was higher than that of group A. The levels of HbA1c in group B were significantly lower than those in group A At the same time, HOMA insulin resistance index and insulin sensitivity index can be decreased, the effect of B group is better than that of A group, and the incidence of hypoglycemia in B group is less than that of A group. Conclusions: Mitiglinid and repaglinide combined with metformin can shorten the blood sugar level of newly diagnosed type 2 diabetic patients in the short term. Mitiglinid and metformin can more effectively improve the indexes of diabetic patients after mid-term treatment.